Edison Investment Research - BC Iron (BCI) BCI Minerals - Termination of coverage

Report

Edison Investment Research

Alison Turner

BCI Minerals - Termination of coverage

Edison Investment Research is terminating coverage on BCI Minerals (BCI) and Sunesis Pharmaceuticals (SNSS). Please note you should no longer rely on any previous research or estimates for these companies. All forecasts should now be considered redundant.

29/09/2020 1 EN

Underlying

BC Iron

BC Minerals is engaged in operation, development and exploration of mineral projects, focusing primarily on iron ore deposits in the Pilbara region of Western Australia.

See profile

AU000000BCI0 Australian Securities Exchange Australia

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Alison Turner

Other Reports on these Companies

MarketLine

Mount Gibson Iron Ltd - Company Profile and SWOT Analysis

Summary Mount Gibson Iron Ltd - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Mount Gibson Iron Ltd (Mount Gibson) is a producer of iron ore in Australia. The company is involved in the mining, exploration, and development of iron ore deposits in Australia. It operates Extension Hill hematite project in the Mt Gibson ranges, southeast of Geraldton. The company through its...

EUR 163.28

December 30, 2023 December 30, 2023 1 EN

MarketLine

Argosy Minerals Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances

Summary Marketline's Argosy Minerals Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Argosy Minerals Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity un...

EUR 326.55

August 28, 2023 August 28, 2023 1 EN

Melrose Industries - Steady climb

Melrose Industries continues to deliver strong performance improvements and is on track to achieve its ambitious margin targets in 2025 (Engines 28% and Structures 9%). As a focused aerospace group, Melrose is also benefiting from the positive long-term drivers in the sector with record civil order backlog. This bodes well for continued earnings momentum and cash generation to drive shareholder value.

1h / 28m 1h / 28m 1 EN

Martyn King

Martyn King

Picton Property Income - Unlocking value to drive DPS growth

Ahead of FY24 results to be published on 23 May, Picton Property Income has declared a Q424 DPS of 0.925p, a 5.7% increase on the previous quarter. The company intends to maintain fully covered dividends at the new level, an annualised run rate of 3.7p, well above the pre-pandemic DPS and the 3.5p paid in respect of FY24. The uplift reflects a continuing robust occupier market, supporting rental growth, as well as asset management activity, most notably the recent sale of Angel Gate. The sale was part of Picton’s strategy to accelerate the unlocking of value in its portfolio through the select...

3h / 31m 3h / 31m 1 EN

Sean Conroy

Sean Conroy

AFT Pharmaceuticals - Maxigesic IV’s Brazil entry, a foray into LATAM

AFT continues to expand its Maxigesic IV footprint with the announcement of a licensing agreement in Brazil, the largest pharma market in South America and tenth largest market globally. The deal signed with Halex Istar, a leading manufacturer of injectables in the country, provides a strong foundation for further extension into the Latin American and global markets, an overarching long-term goal for AFT. Maxigesic IV is a higher-strength version of AFT’s proprietary paracetamol plus ibuprofen formulation targeting post-surgical pain relief in the hospital setting. It is currently available in...

3h / 46m 3h / 46m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BCI Minerals - Termination of coverage

Mount Gibson Iron Ltd - Company Profile and SWOT Analysis

Argosy Minerals Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances

Melrose Industries - Steady climb

Picton Property Income - Unlocking value to drive DPS growth

AFT Pharmaceuticals - Maxigesic IV’s Brazil entry, a foray into LATAM

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe